Sócrates Aedo

Dr. Sócrates Aedo

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Climacteric
Verified
Journal Article
Closed access
MVM. S. Vallejo
M. S. Vallejo
JBJ. E. Blümel
J. E. Blümel
EAE. Arteaga
E. Arteaga
SASócrates Aedo
Sócrates Aedo
VTV. Tapia
V. Tapia
Camil Castelo-BrancoCamil Castelo-Branco
Camil Castelo-Branco
Aim: This study aimed to study the prevalence of vitamin D deficiency, assessing the influence of sex, age, and season of the year. Methods: A cross-sectional study was conducted with 1329 healthy subjects (668 women and 661 men) aged 18–89 years in Santiago, Chile. Age (years), body mass index, medical history, working status, sex, and date of blood sample were collected. Results: Men were slightly older than women (53.1 ± 18.2 vs. 50.0 ± 15.6 years; p < 0.01) and a higher percentage worked outside the home (73.1% vs. 51.9%, p < 0.001). The mean serum concentration of 25-hydroxyvitamin D (25(OH)-D) was 23.3 ± 9.3 ng/ml in women and 20.9 ± 9.5 ng/ml in men (p < 0.001). The levels of 25(OH)-D by season were 26.7 ± 9.0, 23.6 ± 9.7, 19.4 ± 8.5, and 19.1 ± 9.5 ng/ml (for summer, fall, winter, and spring, respectively; p < 0.05). The prevalence of vitamin D deficiency increases with age, rising from 36.5% under 40 years to 48.0% over 60 years (p < 0.004). Male sex, winter and spring, and age showed negative correlation with levels of 25(OH)-D (p < 0.05). Multivariate linear regression showed a final model that incorporates: age (coefficient: −0.06; 95% confidence interval [CI]: −0.09 to −0.03; p < 0.001), male sex (coefficient: −2.00; 95% CI: −2.96 to −1.05; p < 0.001), summer (coefficient: 7.30; 95% CI: 6.17 to 8.43; p < 0.001), and fall (coefficient: 4.27; 95% CI: 3.04 to 5.50; p < 0.001). Conclusions: Vitamin D deficiency is more prevalent in men than in women, in the elderly, and during the winter and spring seasons.

29 January 2020 in Gynecological Endocrinology
Verified
Journal Article
Closed access
JBJuan E. Blümel
Juan E. Blümel
EAEugenio Arteaga
Eugenio Arteaga
SASócrates Aedo
Sócrates Aedo
JAJosé Arriola-Montenegro
José Arriola-Montenegro
MLMarcela López
Marcela López
PCPeter Chedraui
Peter Chedraui
Metformin may decrease cell senescence, including bone; hence we aimed at evaluating the association between metformin use and osteoporosis. This was a cross-sectional study carried out in 1259 Latin American adult women aged 40 or more who were not on anti-osteoporotic drugs, were on metformin and had a bone densitometry performed. Of the whole sample, 40.3% reported being on metformin (at least 1 year), 30.2% had type 2 diabetes mellitus and 22.6% had osteoporosis. Median (interquartile range) body mass index (BMI) for the whole cohort was 27.7 (4.6) kg/m2 and 30.2% had type 2 diabetes mellitus. Current use of hormone therapy, calcium, and vitamin D corresponded respectively to 10.7%, 47.7%, and 43.1% of all surveyed women. A logistic regression model was used to analyze the association of osteoporosis with various covariates incorporated into the model such as age (OR: 1.07, 95% CI: 1.05–1.09), BMI (OR: 0.92, 95% CI: 0.89–0.96) and metformin use (OR: 0.44, 95% CI: 0.32–0.59). Metformin use, regardless of the presence of type 2 diabetes or obesity, was associated with a lower risk of osteoporosis in adult women. We propose that one explanation for this observation could be the effect of the drug over cellular senescence.

Verified
Journal Article
Open access
PDF file
GAGabriel Aedo
Gabriel Aedo
MMMarco Antonio Chahuan Miranda
Marco Antonio Chahuan Miranda
EGElsa Gatica
Elsa Gatica
IHIsabel Herrera
Isabel Herrera
LPLuis Parada
Luis Parada
DADiego Aragón-Caqueo
Diego Aragón-Caqueo
Rosacea is a common chronic inflammatory condition primarily affecting middle-aged women. It presents with flushing, erythema, telangiectasia, papules, pustules, phymatous changes, and ocular involvement. Although typically grouped into four subtypes—erythematotelangiectatic, papulopustular, ocular, and phymatous—overlapping features often favor a phenotypic diagnostic approach. Neurogenic rosacea (NR) has emerged as a distinct subgroup featuring distinguishing features such as peripheral facial erythema, severe burning and stinging sensations, and resistance to standard rosacea therapies. Recent insights into the pathophysiology of NR propose neural dysregulation as the main driver of the condition. Specifically, the activation of TRP channels at cutaneous sensory nerve endings in the dermis triggers the release of vasoactive peptides, driving neuroinflammation and resulting in burning and stinging. Additionally, there is a marked association with neuropsychiatric comorbidities, which would further mediate the pathogenesis of the condition. In line with this pathophysiological model, NR often fails to respond to conventional rosacea treatments. Instead, patients benefit more from antidepressants and neuroleptic agents that help modulate neuronal activity and alleviate symptoms. This review explores and summarizes the scientific evidence regarding the new insights on disease pathogenesis, clinical manifestations, and proposed treatments for NR.

25 November 2015 in BJU International
Verified
Journal Article
Open access
PDF file
NMNigel Murray
Nigel Murray
SASócrates Aedo
Sócrates Aedo
EREduardo Reyes
Eduardo Reyes
NONelson Orellana
Nelson Orellana
CFCynthia Fuentealba
Cynthia Fuentealba
OJOmar Jacob
Omar Jacob
Objective: To establish a prediction model for early biochemical recurrence based on the Cancer of the Prostate Risk Assessment ( CAPRA ) score and the presence of secondary circulating prostate cells ( CPC s). Patients and Methods: We conducted a prospective single‐centre study of men who underwent radical prostatectomy as monotherapy for prostate cancer. Clinicopathological findings were used to calculate the CAPRA score. At 90 days after surgery, blood was taken for CPC detection, mononuclear cells were obtained using differential gel centrifugation, and CPC s were identified using immunocytochemistry. A CPC was defined as a cell expressing prostate‐specific antigen ( PSA ) but not CD 45. The CPC test results were defined as positive or negative. Patients were followed up for up to 5 years and biochemical recurrence was defined as a PSA level >0.2 ng/mL. The validity of the CAPRA score was calibrated using partial validation, and Cox proportional hazard regression to build three models: a CAPRA score model, a CPC model and a CAPRA / CPC combined model. Results: A total of 321 men, with a mean age of 65.5 years, participated in the study. After 5 years of follow‐up the biochemical recurrence‐free survival rate was 98.55%. For the model that included CAPRA score there was a hazard ratio ( HR ) of 7.66, for the CPC model there was an HR of 34.52 and for the combined model there were HR s of 2.60 for CAPRA score and 22.5 for CPC . Using the combined model, 23% of men changed from the low‐risk to the high‐risk category, or vice versa. Conclusion: The incorporation of CPC detection significantly improved the model's discriminative ability in establishing the probability of biochemical recurrence; patients in the high‐risk group according to CAPRA score who are negative for CPC s have a much better prognosis. The addition of CPC detection gives clinically significant information to aid the decision on who may be eligible for adjuvant therapy.

18 November 2019 in Climacteric
Verified
Journal Article
Closed access
SASócrates Aedo
Sócrates Aedo
JBJ. E. Blümel
J. E. Blümel
RCRodrigo M Carrillo-Larco
Rodrigo M Carrillo-Larco
MVM. S. Vallejo
M. S. Vallejo
GAG. Aedo
G. Aedo
ICI. Campodónico
I. Campodónico
Introduction: In women, bone mineral density (BMD) is related to age, estrogenic action, and appendicular skeletal muscle mass (ASMM). The gynoid fat distribution is linked to estrogenic action. Objective: This study aimed to assess whether an increase of gynoid fat is associated with high BMD independent of age and ASMM. Methods: An observational study was performed in women aged between 20 and 79 years. Fat mass, ASMM, and BMD were measured with dual-energy X-ray absorptiometry. The binned scatterplots and multivariate linear regression models were used to study the relationship between hip BMD and age, height, android fat, gynoid fat, and ASMM. Results: Of 673 women invited, 596 accepted to participate. Their mean age was 55.4 ± 12.8 years, weight 63.4 ± 9.4 kg, height 1.61 ± 0.06 m, body mass index 24.54 ± 3.59 kg/m2, average hip BMD 0.914 ± 0.122 g/cm2, android fat 2.12 ± 0.83 kg, gynoid fat 4.54 ± 1.07 kg, and ASMM 15.15 ± 1.97 kg. The final regression model included age (linear coefficient −0.004; 95% confidence interval [CI]: −0.005 to −0.003; p < 0.001), ASMM (linear coefficient 0.013; 95% CI: 0.009 to 0.018; p < 0.001), and gynoid fat (linear coefficient 0.013; 95% CI: 0.005 to 0.022; p < 0.002). Conclusion: Gynoid fat is associated with BMD in the hip independently of age and ASMM.